ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0014072 | An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) | Experimental Encephalomyelitis, Autoimmune|Autoimmune Encephalomyelitis, Experimental|Allergic encephalomyelitis (disorder)|Autoimmune Experimental Encephalomyelitis|experimental allergic encephalomyelitis|Allergic encephalomyelitis|Experimental Allergic Encephalomyelitis|Experimental allergic encephalomyelitis|Experimental allergic encephalomyelitis (disorder)|Experimental Allergic Encephalomyelitides|Allergic Encephalomyelitis, Experimental|Encephalomyelitis, Experimental Autoimmune|eae|Encephalomyelitis, Allergic|Encephalomyelitis, Experimental Allergic|Allergic Encephalomyelitis|autoimmune encephalomyelitis|experimental autoimmune encephalomyelitis (EAE)|Experimental Autoimmune Encephalomyelitis|Encephalomyelitis, Autoimmune Experimental|Encephalomyelitis, Autoimmune, Experimental|EAE | Experimental Autoimmune Encephalomyelitis |
C0053602 | null | bilirubin NAD(P) oxidoreductase|Biliverdin reductase (substance)|biliverdin reductase|Biliverdin reductase | Biliverdin reductase |
C0005437 | A bile pigment that is a degradation product of HEME. | Bilirubin IX alpha|Bilirubin, total|Conjugated and unconjugated bilirubin|bilirubin|Total bilirubin|21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-|Bilirubin|Bilirubin, NOS|BILIRUBIN|Bilirubin (substance)|total bilirubin | Bilirubin |
C0965324 | null | null | dichlorofluorescin |
C0007188 | Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS. | Cardiac lipoprotein (substance)|cardiolipin|Cardiac lipoprotein|Cardiolipin|cardiolipins | Cardiolipins |
C1327192 | null | null | organelle ATP synthesis coupled electron transport |
C0038563 | The various filaments, granules, tubules or other inclusions within mitochondria. | Particles, Submitochondrial|Submitochondrial Particle|Particle, Submitochondrial | Submitochondrial Particles |
C0206064 | A disorder affecting the smallest coronary arteries. Causes include atherosclerosis and arterial spasm. Chest pain is a frequently observed symptom. | Coronary microvascular disease|CMD|syndrome x|Coronary Microvascular Disease|Angina Syndrome Xs|Coronary small artery disease|Angina X Syndromes|Microvascular Angina|Syndrome X, Angina|Syndrome Xs, Angina|Cardiac Syndrome X|Syndrome X, Cardiac|Angina X Syndrome|cardiac syndrome x|Microvascular angina|Syndrome X (Cardiac)|Syndrome, Angina X|Angina Pectoris with Normal Coronary Arteriogram|X Syndrome, Angina|Angina, Microvascular|Cardiac syndrome X|Chest pain with normal coronary angiography|Angina Syndrome X|Cardiac syndrome X (finding)|microvascular angina | Microvascular Angina |
C0947751 | null | vascular inflammation|inflammation vascular | vascular inflammations |
C0038836 | Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides. | Superoxide Radical|superoxide|Superoxide|Superoxides|superoxide radical|superoxide anion|Superoxide Anion | Superoxides |
C0759009 | null | null | heme 1 |
C0030660 | The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. | Pathological process (attribute)|Pathologic Process|Pathological process|PATHOLOGICAL DISORDERS|Processes, Pathological|pathological disorders|pathologic process|pathological disorder|pathological processes|Processes, Pathologic|Pathological process (qualifier value)|Pathological Processes|pathological process | Pathologic Processes |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0083727 | A BRAIN-specific substrate for PROTEIN KINASE C that binds CALMODULIN and is involved in regulation of CALCIUM SIGNALING. | Neurogranin|RC3 Protein (Neurogranin)|P17 Protein Kinase C Substrate | Neurogranin |
C0376446 | Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) | Agents, Reducing|reducing agents|Reductants|reducing agent | Reducing Agents |
C0162574 | Nonenzymatically glycosylated proteins or lipids which accumulate in vascular tissue during aging and at an accelerated rate in diabetes. | Advanced Glycation End Product|Maillard Products|Glycation Endproducts, Advanced|Advanced Glycosylation End Products|advanced glycosylation end products|Advanced Glycation End-Product|Glycosylation End Products, Advanced|Advanced Glycosylation Endproducts|Maillard Reaction Products|Products, Maillard|Advanced Maillard Reaction End Products|advanced end glycosylation products|Advanced Glycation Endproducts|Reaction Products, Maillard|Advanced Glycation Endproduct|Products, Maillard Reaction|Advanced Glycosylation End Product|Glycosylation Endproducts, Advanced|Maillard Reaction End Products|Endproducts, Advanced Glycosylation|advanced glycation end products|Advanced Glycation End Products|Endproducts, Advanced Glycation|AGEs | Glycation End Products, Advanced |
C0018358 | An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2. | Cyclase, Inosinate|Cyclase, Guanylate|Guanylyl Cyclase|Guanyl Cyclase|GTP pyrophosphate-lyase (cyclizing)|Cyclase, Guanylyl|Cyclase, Deoxyguanylate|Deoxyguanylate Cyclase|guanylyl cyclase|EC 4.6.1.2|guanyl cyclase|Guanyl cyclase|guanylate cyclase|Guanylate cyclase (substance)|Guanylyl cyclase|Guanylate Cyclase|Cyclase, Guanyl|Guanylate cyclase|Inosinate Cyclase | Guanylate Cyclase |
C0011134 | A compound used as a topical insect repellent that may cause irritation to eyes and mucous membranes, but not to the skin. | N,N-diethyl-m-toluamide|dietiltoluamida|det|N,N-Diethyl-3-methylbenzamide|3-methyl-N,N-diethylbenzamide|deets|Deet|DEET N,N-DIETHYL-META-TOLUAMIDE|Diethyltoluamide (substance)|diethyltoluamidum|DETA|N,N-Diethyl-m-toluamide|N,N Diethyltoluamide|deet|diéthyltoluamide|Diethyltoluamide|DEET|DET|Diethyl toluamide|N,N Diethyl 3 methylbenzamide|N,N Diethyl m toluamide|diethyl toluamide|Benzamide, N,N-diethyl-3-methyl-|DIETHYLTOLUAMIDE|diethyltoluamide|deta|N,N-Diethyltoluamide | diethyltoluamide |
C0007608 | Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another. [GOC:dgh, GOC:dph, GOC:isa_complete, GOC:mlg] | cell movement|Cell Motility|cells movement|cell locomotion|Motility|cell motility|Locomotion, Cell|Motility, Cellular|movement of a cell|Motility, Cell|Cell Locomotion | cell motility |
C0041904 | A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. | Up-Regulation|Up-Regulation (Physiology)|up regulation|up-regulation|Up Regulation|Upregulation|upregulation | Up-Regulation (Physiology) |
C0056820 | null | null | cyclosporin diaziridine |
C0056820 | null | null | cyclosporin diaziridine |
C0005698 | Insertion of an endosseous implant with a narrow wedge-shaped infrastructure extending through the oral mucosa into the mouth and bearing openings or vents through which tissue grows to obtain retention. | Blade Implantations|Implantations, Blade|Implantation, Blade | Blade Implantation |
C0037841 | The structural and functional changes by which SPERMATOZOA become capable of oocyte FERTILIZATION. It normally requires exposing the sperm to the female genital tract for a period of time to bring about increased SPERM MOTILITY and the ACROSOME REACTION before fertilization in the FALLOPIAN TUBES can take place. | sperm capacitation|Capacitation of Spermatozoa|Spermatozoa Capacitation|Capacitation, Sperm | Sperm Capacitation |
C1373060 | Any substance that inhibits nitric oxide synthase, an enzyme that catalyzes the production of nitric oxide from L-arginine. Nitric oxide is an important intercellular signaling molecule and inhibition of nitric oxide synthase effects many wide-ranging body processes and systems. | Nitric Oxide Synthase Inhibitor|Nitric Oxide Synthetase Inhibitor|NOS Inhibitor | Nitric Oxide Synthase Inhibitor |
C0036647 | Degenerative changes of the cornea related to aging that are highly influenced by changes in the corneal endothelium. Changes include corneal topography, increased density, decreased hydration of the corneal stroma, and epithelial basement membrane dystrophy; The stroma appears hazier than in younger eyes and reduces light transmission. Changes may also include age-related stromal degeneration and deposition. | Senile corneal changes|Senile corneal changes (disorder)|Senile Corneal Change | Senile corneal changes |
C0036647 | Degenerative changes of the cornea related to aging that are highly influenced by changes in the corneal endothelium. Changes include corneal topography, increased density, decreased hydration of the corneal stroma, and epithelial basement membrane dystrophy; The stroma appears hazier than in younger eyes and reduces light transmission. Changes may also include age-related stromal degeneration and deposition. | Senile corneal changes|Senile corneal changes (disorder)|Senile Corneal Change | Senile corneal changes |
C0633227 | A family of ubiquitously-expressed peroxidases that play a role in the reduction of a broad spectrum of PEROXIDES like HYDROGEN PEROXIDE; LIPID PEROXIDES and peroxinitrite. They are found in a wide range of organisms, such as BACTERIA; PLANTS; and MAMMALS. The enzyme requires the presence of a thiol-containing intermediate such as THIOREDOXIN as a reducing cofactor. | Peroxiredoxins|Peroxiredoxin|Protector Protein (Mixed-Function Oxidase Systems)|Thiol-Specific Antioxidant Protein|Alkyl Hydroperoxide Reductase|Alkylhydroperoxide Reductase|Hydroperoxide Reductase, Alkyl|Thiol Specific Antioxidant Protein|Peroxidoxin|Thioredoxin Peroxidase | thioredoxin peroxidase |
C0023206 | Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition. | lectin|Lectin (substance)|Lectin, NOS|lectins|Lectin|Lectins | Lectin |
C0494463 | null | Alzheimer's disease with late onset|Primary degenerative dementia of the Alzheimer type, senile onset (disorder)|Dementia of the Alzheimers type, late onset|Late Onset Alzheimer Disease|SDAT - Senile dementia, Alzheimer's type|Primary degenerative dementia of the Alzheimer type, late onset|Primary degenerative dementia of the Alzheimer type, senile onset|Dementia in Alzheimer's disease - type 1|Dementia in Alzheimer's disease with late onset | Alzheimer Disease, Late Onset |
C0039730 | A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. | thalassemia|Thalassaemia syndrome|Thalassemia syndrome, NOS|Thalassemias|Thalassemia, unspecified|Thalassemia syndrome|Thalassemic syndrome|Thalassemia NOS|Thalassemia syndrome (disorder)|Hereditary leptocytosis|Thalassemia (disorder)|Thalassemia, NOS|thalassaemia|thalassaemias|THALASSEMIAS|thalassemias|Thalassemic Syndromes|Thalassaemia|Thalassemia|syndromes thalassemia|thalassemia disorder|THALASSEMIA | Thalassemia |
C0005221 | Members of the beta-globin family. In humans, they are encoded in a gene cluster on CHROMOSOME 11. They include epsilon-globin, gamma-globin, delta-globin and beta-globin. There is also a pseudogene of beta (theta-beta) in the gene cluster. Adult HEMOGLOBIN is comprised of two ALPHA-GLOBIN chains and two beta-globin chains. | beta-globin|beta Globins|Non-alpha Globin Chain, Unspecified|beta Globin|beta-Globin|Non alpha Globin Chain, Unspecified|beta-Globins|beta globin | beta-Globins |
C0005283 | A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent. | Beta thalassaemia syndrome|Cooley anemia|Beta thalassemia|Type Microcytemia, beta|Type Thalassemia, beta|beta Thalassemia|Type Microcytemias, beta|beta thalassemia|beta thalassaemia|Beta Thalassemia|Type Thalassemias, beta|Microcytemias, beta Type|beta Type Microcytemia|beta-thalassaemia|Beta thalassaemia|beta Thalassemias|beta Type Thalassemias|Thalassemia Major|beta-Thalassemia|Thalassemias, beta Type|beta Type Microcytemias|beta Thalassemia, NOS|Microcytemia, beta Type|Beta thalassemia syndrome|Cooley's anemia|Thalassemia, beta Type|Thalassemias, beta|beta-thalassemia|Beta thalassemia (disorder)|thalassaemia beta|thalassemia major|Thalassemia, beta|beta Type Thalassemia|thalassemia beta|beta thalassemias|BETA-THALASSEMIA | beta Thalassemia |
C0200695 | The determination of the amount of hemoglobin F present in a sample. | Fetal Hemoglobin|HGBF|Hemoglobin determination, fetal|Fetal hemoglobin determination|Hemoglobin F Measurement|Haemoglobin F level|Fetal haemoglobin determination|Foetal haemoglobin determination|Hemoglobin F|foetal haemoglobin|Fetal hemoglobin determination (procedure)|Hemoglobin F level|fetal hemoglobin | Fetal hemoglobin determination |
C0062337 | null | hemoglobin Hope|Hb 136(H14), Gly-asp, beta chain|Hemoglobin Hope|Hemoglobin Hope (substance)|Hb Hope|Hb, beta-136 Gly-Asp|Haemoglobin Hope | Hemoglobin Hope |
C0702157 | null | Thalassemia trait, NOS|thalassaemia trait|Heterozygous thalassaemia|Heterozygous thalassemia (disorder)|Heterozygous thalassemia, NOS|thalassemia trait|thalassemia traits|Thalassaemia trait|Thalassemia trait NOS|Heterozygous thalassemia|Thalassemia trait|heterozygous thalassemia|THALASSEMIA TRAIT | Thalassemia trait |
C0271980 | null | beta zero thalassaemia|Beta 0 thalassemia|beta zero thalassemia|Beta 0 thalassaemia|Beta zero thalassaemia|Beta zero thalassemia (disorder)|beta0 Thalassemia, NOS|beta O Thalassemia|BETA-ZERO-THALASSEMIA | Beta zero thalassemia |
C0457279 | null | Cord blood specimen (specimen)|Cord blood sample | Cord blood specimen |
C0062251 | null | hemoglobin bart's|Hb - Hemoglobin Barts|Hb gamma4|methemoglobin Bart's|Haemoglobin Barts|haemoglobin barts|barts hemoglobin|Hemoglobin Barts|Hb Bart's|Haemoglobin Bart|hemoglobin bart|Hemoglobin Bart|bart's hemoglobin|hemoglobin Barts|hemoglobin barts|Hb - Haemoglobin Barts|Hemoglobin Bart's|hemoglobin Bart's|Hemoglobin Bart (substance) | Hemoglobin Bart's |
C1517598 | Iron Chelation involves non-covalent coordination bonding between iron and an organic chemical, often as part of an enzyme or protein complex, as in the iron-binding porphyrin group of hemoglobin. | Iron Chelating|Iron Chelation | Iron Chelation |
C0043832 | An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. | 4(1H)-pyridinone, 3-hydroxy-1,2-dimethyl-|4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-|DMOHPO|Deferiprone (substance)|Deferiprone-containing product|Défériprone|deferiprone|1,2 Dimethyl 3 hydroxy 4 pyridinone|HDMPP|Product containing deferiprone (medicinal product)|DEFERIPRONE|1,2 Dimethyl 3 hydroxypyrid 4 one|3 Hydroxy 1,2 dimethyl 4 pyridinone|1,2-Dimethyl-3-hydroxy-4-pyridinone|3-Hydroxy-1,2-dimethyl-4(1H)-pyridone|1,2-Dimethyl-3-hydroxypyridin-4-one|Deferiprone|Deferiprona|Deferipronum|1,2 Dimethyl 3 hydroxypyridin 4 one|1,2-Dimethyl-3-hydroxypyrid-4-one|3-Hydroxy-1,2-dimethyl-4-pyridinone | deferiprone |
C0376541 | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo). Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04) | Erythropoiesis stimulating factor|Erythropoietin|ERYTHROPOIETIN|erythropoietin recombinant|SH-polypeptide-72|Hematopoietin|recombinant erythropoietin|Erythrocyte Colony Stimulating Factor|Recombinant EPO|Erythropoietin (recombinant human)|ESF|r-HuEPO|Erythropoietin (human, recombinant)|Recombinant Erythropoietin | Recombinant Erythropoietin |
C0015625 | Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004) | Fanconi Panmyelopathy|Fanconi's familial refractory anaemia|Fanconi anaemia|PRIMARY ERYTHROID HYPOPLASIA|constitutional aplastic anemia|Pancytopenia, Congenital|Fanconi Anemias|congenital pancytopenia|anemia fanconi|anemia fanconis|Fanconi's Anemia|Panmyelopathy, Fanconi|FA|anemia fanconi's|fanconi anemias|FANCONI'S ANEMIA|Anemias, Fanconi|Fanconi anemia|Fanconi's hypoplastic anemia|fanconi syndrome|Fanconi's familial refractory anemia|fanconi's anemia|PANMYELOPATHY, FANCONI|Fanconi's pancytopenia syndrome|Fanconi's hypoplastic anaemia|Fanconi's anemia (disorder)|FANCONI ANEMIA|PANCYTOPENIA, CONGENITAL|Fanconi's anaemia|congenital aplastic anemia|Anemia, Fanconi|Primary Erythroid Hypoplasia|Fanconi pancytopenia syndrome|Anemia, Fanconi's|Fanconi Hypoplastic Anemia|fanconis syndrome|fanconi anemia|Fanconi Anemia|Fanconi Pancytopenia|Fanconi's anemia|fanconi's anaemia | Fanconi Anemia |
C0038838 | An oxidoreductase that catalyzes the reaction between SUPEROXIDES and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. | Erythrocuprein|superoxide dismutases|Hemocuprein|superoxide dismutase|sod|cytocuprein|Superoxide dismutase|SOD|E.C. 1.15.1.1|SUPEROXIDE DISMUTASE|Superoxide Dismutase (SOD)|Superoxide:superoxide oxidoreductase|Superoxide dismutase (substance)|Dismutase, Superoxide|super oxide dismutase|Superoxide Dismutase | superoxide dismutase |
C0002875 | The most severe form of beta thalassemia that is characterized by the lack of functional beta-globin chain production resulting in the absence of hemoglobin A. | Cooley Anemia|anemia cooley's|Anemia, Cooley's|COOLEY ANEMIA|Beta thalassaemia major|Majors, Thalassemia (beta-Thalassemia Major)|major thalassemia|Homozygous thalassemia|mediterranean anaemia|THALASSEMIA MAJOR|Mediterranean anemia|Cooley's Anemia|BETA THALASSEMIA MAJOR|Anemias, Erythroblastic|ANEMIA, MEDITERRANEAN|Cooley's anaemia|thalassaemia major|beta thalassemia major|Anemia, Cooley|Mediterranean anaemia|beta thalassaemia major|Homozygous thalassemia, NOS|ANEMIA, HEMOLYTIC, THALASSEMIA MAJOR|Mediterranean Anemias|Anemia, Erythroblastic|Thalassemia Major|cooley anemia|Homozygous thalassaemia|Homozygous beta thalassaemia|beta Thalassemia, homozygous|Anemia, Mediterranean|Thalassaemia major|Mediterranean Anemia|Beta Thalassemia Major|Cooley's anemia|Thalassemia major (disorder)|Thalassemia major|Erythroblastic Anemia|cooley's anemia|mediterranean anemia|Thalassemia Major (beta-Thalassemia Major)|Anemias, Mediterranean|Thalassemia Majors (beta-Thalassemia Major)|Major, Thalassemia (beta-Thalassemia Major)|cooleys anemia|Thalassemia Major (beta Thalassemia Major)|Beta thalassemia major|Thalassemia major, NOS|thalassemia major|Anemia, Cooleys|Homozygous beta thalassemia (disorder)|cooley's anaemia|Homozygous beta thalassemia|homozygous beta thalassemia | Cooley's anemia |
C0007975 | Therapy of heavy metal poisoning using agents which sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound which can be eliminated from the body. | therapy chelation|Chelation therapy|Therapy, Chelation|Chelation Therapies|chelation therapy|Therapies, Chelation | Chelation Therapy |
C0022408 | Diseases involving the JOINTS. | arthropathic|Joint Diseases|ARTHROPATHY, NOS|Disorder of joint, NOS|arthropathy nos|Joint Disorders|Arthropathy (disorder)|joint disorders|Disorder of joint|Joints--Diseases|joint disease|ARTHROPATHY|Arthropathy|Arthropathy, NOS|Joint Disorder|Arthrosis|Arthrosis, NOS|arthropathy|joint dysfunction|Disease of joint|articular disease|ARTHROPATHY (NOS)|Arthropathies|diseases of joints|Unspecified disorder of joint, site unspecified|Joint disorder|DISORDER JOINT|Joint disease, NOS|diseases of the joints|Unspecified disorder of joint|arthropathies|Arthropathy, unspecified, site unspecified|Joint Disease|ARTHROSIS|Articular disease|Disorder, Joint|Diseases of Joints|joint diseases|joint disorder|DISEASES OF THE JOINTS|Joint disease|arthrosis|JOINT DISORDER|Disease of the joints|Arthropathy, unspecified | Arthropathy |
C0877248 | An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse effects do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe. | AE|Adverse Event|Adverse Experience|adverse event (AE)|adverse events|adverse experience|ADVERSE EVENT|Adverse event|side effects|AdverseEvent|adverse event | Adverse event |
C0005961 | The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. | Marrow Transplantation|Transplantation of bone marrow, NOS|Bone marrow graft|Transfusion of bone marrow|bmt|Transplantation of bone marrow|Transplantation of bone marrow (procedure)|bone marrow transplant bmt|bone marrow transplants|Bone marrow transplant, not otherwise specified|Grafting, Bone Marrow|bone marrow grafting|bone marrow transplant|bone marrow transplant (BMT)|Transplantation, Bone Marrow|BMT - Bone marrow transplant|BMT|bone marrow transplantation|Bone Marrow Transplant|bone marrow transplantations|transplantation, bone marrow|Bone marrow transplant|BONE MARROW TRANSPLANT|Bone Marrow Transplantation|Bone marrow transplantation|Bone Marrow Grafting|Bone marrow--Transplantation|bone marrow graft|Blood and Bone Marrow Transplant | Bone Marrow Transplantation |
C0022086 | Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. | chelates iron|iron chelates|Chelated iron (substance)|Iron chelating agents|Iron Chelates|Iron chelates|chelated iron|chelate iron|iron chelate|Iron Chelating Agents|chelating iron|iron chelating|Chelates, Iron|Agents, Iron Chelating|Chelating Agents, Iron|agent chelating iron|Chelated iron | Iron Chelating Agents |
C0034272 | The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). | pyridoxine|Piridoxina|Pyridoxin|2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine|Pyridoxine-containing product|pyridoxine (vit B6)|Pyridoxine|Vitamin B6|5-hydroxy-6-methyl-3,4-pyridinedimethanol|PYRIDOXINE|pyridoxin|3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine|Pyridoxinum|3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-|Pyridoxine (substance)|Pyridoxine preparation|pyridoxol|Pyridoxol|3-hydroxy-4,5-dimethylol-α-picoline|Product containing pyridoxine (medicinal product) | pyridoxine |
C0034272 | The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). | pyridoxine|Piridoxina|Pyridoxin|2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine|Pyridoxine-containing product|pyridoxine (vit B6)|Pyridoxine|Vitamin B6|5-hydroxy-6-methyl-3,4-pyridinedimethanol|PYRIDOXINE|pyridoxin|3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine|Pyridoxinum|3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-|Pyridoxine (substance)|Pyridoxine preparation|pyridoxol|Pyridoxol|3-hydroxy-4,5-dimethylol-α-picoline|Product containing pyridoxine (medicinal product) | pyridoxine |
C1513400 | Analysis of the RNA expression pattern in a tissue sample using molecular techniques. | Molecular Fingerprinting|Expression Signature|Molecular Profiling|Expression Profiling|Molecular Signature | Molecular Profiling |
C0015683 | Fatty acid synthase (2511 aa, ~273 kDa) is encoded by the human FASN gene. This protein is involved in long-chain fatty acid synthesis. | Fatty-acid synthase|fatty acid synthase|FAS|Fatty Acid Synthase|FASN|Fatty-acid synthase (substance)|EC 2.3.1.85 | Fatty-acid synthase |
C0015683 | Fatty acid synthase (2511 aa, ~273 kDa) is encoded by the human FASN gene. This protein is involved in long-chain fatty acid synthesis. | Fatty-acid synthase|fatty acid synthase|FAS|Fatty Acid Synthase|FASN|Fatty-acid synthase (substance)|EC 2.3.1.85 | Fatty-acid synthase |
C0071462 | null | null | poly(rA).oligo(dT) |
C0071462 | null | null | poly(rA).oligo(dT) |
C0085437 | Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots. | Bacterial Meningitides|Bacterial Meningitis|Bacterial meningitis|bacterial meningitis|MENINGITIS, BACTERIAL|Meningitis, bacterial NOS|Meningitis due to unspecified bacterium|BM - Bacterial meningitis|Meningitis, bacterial|bacterial meningitides|Meningitides, Bacterial|Bacterial meningitis (disorder)|Bacterial meningitis, NOS | Meningitis, Bacterial |
C0887947 | Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. | Highly Active Antiretroviral Therapy|Highly active anti-retroviral therapy (procedure)|HAART-Highly active anti-retroviral therapy|haart|HAART (highly active antiretroviral therapy)|highly active retroviral therapy|Highly active anti-retroviral therapy|highly active antiretroviral therapy|HAART | Antiretroviral Therapy, Highly Active |
C0343804 | null | Chronic Chagas' disease (disorder) | Chronic Chagas' disease |
C0023343 | A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. | Hansen's Disease|hansen's disease|Leprosy|Leprosy, unspecified|Infection due to Mycobacterium leprae|Leprosy (disorder)|hansens disease|Mycobacterium leprae infection|LEPROSY|HANSEN DISEASE|hansen disease|Hansen's disease|leprosy|Leprosy, NOS|Hansen Disease|leprosy nos | Leprosy |
C0007682 | Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. | Central Nervous System Diseases|CNS disorder|disease central nervous system|Central nervous system (CNS) disease|Central nervous system--Diseases|cns diseases|Encephalomyeloneuropathy|Central nervous system disease|Disorder of Central Nervous System|Disease of the central nervous system, NOS|NERVOUS SYSTEM DISORDER, CENTRAL|central nervous system disorders|Central Nervous System Disorder|central disorder nervous system|cns disease|central disease nervous systems|Disorder of the central nervous system|Disorder of the central nervous system (disorder)|CNS Diseases|Encephalomyeloneuropathy, NOS|central disease nervous system|Central Nervous System Disease|CNS DISORDER (NOS)|CNS Disease|DISORDER CENTRAL NERVOUS SYSTEM|central nervous system diseases|cns disorders|CENTRAL NERVOUS SYSTEM DISORDER|central diseases nervous system|central disorders nervous system|central nervous system disorder|cns disorder|Central Nervous System Disorders|Disorder of central nervous system NOS|encephalomyeloneuropathy|central nervous system disease | CNS disorder |
C0270614 | null | Intracranial mass|Intracranial lump|Mass of intracranial structure (finding)|Mass of intracranial structure | Intracranial mass |
C0026976 | Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6) | Transverse Myelopathy Syndromes|Transverse myelitis NOS|Transverse Myelopathy Syndrome|Transverse myelopathy syndrome (disorder)|transverse myelitis|TRANSVERSE MYELITIS ACUTE OR SUBACUTE|Transverse myelitis|myelitis transverse|MYELITIS TRANSVERSE|Transverse Myelitis|Transverse myelopathy syndrome | Myelitis, Transverse |
C0041330 | Osteitis or caries of the vertebrae, usually occurring as a complication of tuberculosis of the lungs. | diseases pott|Tuberculous spondylitis|Spinal Tuberculosis|tuberculous spondylitis|disease potts|spine tuberculous|SPINE, TUBERCULOSIS|spinal cord tuberculosis|spine tb|pott disease|Tuberculosis of spine (Pott's)|Disease, Pott|Tuberculoses, Spinal|Tuberculosis, Spinal|Pott's disease|Disease, Pott's|tuberculosis spine|Pott's Disease|Spine--Tuberculosis|spinal tuberculosis|disease pott's|Tuberculosis of vertebral column, unspecified|tuberculosis of spine|Tuberculosis of vertebral column - Pott's|Tuberculosis of vertebral column|potts disease|tuberculosis spinal|pott's disease|spine tuberculosis|POTT DISEASE|disease pott|tb spine|Pott Disease|TUBERCULOUS SPONDYLITIS|SPONDYLITIS, TUBERCULOUS|Potts Disease|Tuberculosis of vertebral column (disorder)|Spinal Tuberculoses|diseases pott's | Tuberculosis, Spinal |
C0241028 | null | sexually active|active sexually|SEXUALLY ACTIVE|Sexually active (finding) | Sexually active |
C0280803 | A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis. | CNS Lymphoma|primary CNS lymphoma|lymphoma, primary central nervous system|PCNSL - Primary CNS lymphoma|CNS lymphoma, primary|primary cns lymphoma|cns lymphoma|lymphoma, primary CNS|central nervous system lymphoma, primary|cns lymphoma primary|lymphoma cns|Primary central nervous system lymphoma|central lymphoma nervous system|Microglioma (disorder)|primary lymphoma cns|central nervous system lymphoma|Primary CNS Lymphoma|Primary Central Nervous System Lymphoma|Malignant Lymphomas of the CNS|primary central nervous system lymphoma|PCNSL|cns lymphomas|Primary CNS lymphoma|Central Nervous System Lymphoma|Malignant Lymphomas of CNS|Microglioma | Primary central nervous system lymphoma |
C0599855 | null | neurodevelopment | neurodevelopment |
C0040577 | A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) | trace element|elements trace|element trace|Micronutrient|Trace Element|Trace element, NOS|Trace Nutrient|Element, Trace|Trace Mineral|TRACE ELEMENTS|Trace Elements|Elements, Trace|trace elements|Trace elements | Trace Elements |
C0023524 | An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) | Encephalopathies, JC Polyomavirus|Progressive multifocal leukoencephalopathy (disorder)|LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL|Leukoencephalopathy, Progressive Multifocal|multifocal leukoencephalopathy|PMLE - Progressive multifocal leucoencephalopathy|Leukoencephalopathies, Progressive Multifocal|PML|Progressive Multifocal Leukoencephalopathies|Progressive multifocal leucoencephalopathy|Multifocal leucoencephalopathy|PML - Progressive multifocal leukoencephalopathy|PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY|Multifocal Leukoencephalopathy, Progressive|PMLE - Progressive multifocal leukoencephalopathy|pml|JC Polyomavirus Encephalopathy|Progressive Multifocal Leukoencephalopathy|Multifocal leukoencephalopathy, NOS|Progressive multifocal leukoencephalopathy|Encephalitis, JC Polyomavirus|progressive multifocal leukoencephalopathy|PML - Progressive multifocal leucoencephalopathy|Multifocal Leukoencephalopathies, Progressive|Multifocal leukoencephalopathy NOS|Multifocal leukoencephalopathy|JC Polyomavirus Encephalitis|Encephalopathy, JC Polyomavirus | Leukoencephalopathy, Progressive Multifocal |
C1172734 | A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue. Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells. | Natalizumab|Anti-VLA4|NATALIZUMAB|Product containing natalizumab (medicinal product)|Natalizumab-containing product|Anti-alpha4 integrin|natalizumab|Natalizumab (substance) | natalizumab |
C0001849 | A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40) | AIDS dementia|Acquired immune deficiency syndrome dementia complex|Dementia Complex, AIDS Related|HIV Dementias|Complex, AIDS Dementia|HIV-Associated Cognitive Motor Complex|HIV dementia|AIDS with dementia, NOS|HIV Dementia|Dementia associated with AIDS|Acquired-Immune Deficiency Syndrome Dementia Complex|ADC - Acquired immune deficiency syndrome dementia complex|HIV associated cognitive motor complex|AIDS Related Dementia Complex|Acquired immune deficiency syndrome-related dementia|Dementia associated with acquired immunodeficiency syndrome|HIV Associated Cognitive Motor Complex|aids dementia complex|dementia AIDS|Dementia associated with acquired immunodeficiency syndrome (disorder)|AIDS dementia complex|AIDS-Related Dementia Complex|Complex, AIDS-Related Dementia|Dementias, HIV|Dementia Complex, AIDS|aids-related dementia|HIV associated cognitive and motor complex|AIDS Dementia|Dementia Complex, Acquired Immune Deficiency Syndrome|AIDS - Acquired immune deficiency syndrome dementia complex|hiv-related dementia|Dementia Complex, AIDS-Related|dementia HIV|Dementia, HIV | AIDS Dementia Complex |
C0005854 | Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. | Brain Blood Barrier|Barriers, Hemato-Encephalic|Brain-Blood Barriers|Hemato-Encephalic Barrier|Blood-Brain Barrier|barrier blood brain|Barrier, Blood-Brain|BBB|barriers blood brain|blood-brain barriers|Barriers, Brain-Blood|Hemato Encephalic Barrier|Barrier, Hemato-Encephalic|blood-brain barrier|Barrier, Brain-Blood|blood brain barrier|Barriers, Blood-Brain|Hemato-Encephalic Barriers|barrier blood-brain|bbb|brain blood barrier|Blood-Brain Barriers|Blood Brain Barrier|Brain-Blood Barrier|Blood-brain barrier | Blood - brain barrier anatomy |
C1619738 | Exuberant inflammatory response towards a previously acquired or undiagnosed opportunistic infection. It is frequently seen in AIDS patients following antiretroviral treatment. | Immune Restoration Syndrome|Immune Reconstitution Disease|Immune Reconstitution Syndromes|Immune Reconstitution Syndrome|Immune Restoration Disease|Reconstitution Disease, Immune|Reconstitution Syndrome, Immune|Immune Restoration Diseases|Immune Reconstitution Inflammatory Syndrome|Restoration Syndrome, Immune | Immune Reconstitution Inflammatory Syndrome |
C0010414 | Infection with a fungus of the species CRYPTOCOCCUS NEOFORMANS. | torulosis|Torulosis|Cryptococcosis|Infection by Cryptococcus neoformans|European Blastomycosis|Infection, Cryptococcus neoformans|Busse-Buschke's disease|cryptococcus neoformans|Cryptococcus neoformans Infection|torula|cryptococcosis|cryptococcoses|Cryptococcoses|Cryptococcosis, NOS|TORULOSIS|Toruloses|Infection due to Cryptococcus|Torula|Cryptococcosis (disorder)|cryptococcus infection neoformans|Busse-Buschke disease|European blastomycosis|European cryptococcosis|Cryptococcus neoformans Infections|CRYPTOCOCCOSIS | Infection by Cryptococcus neoformans |
C0028589 | Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. | Proteins, Nuclear|Nuclear Proteins|Nuclear proteins|Nuclear Protein|nuclear protein | Nuclear Proteins |
C0056820 | null | null | cyclosporin diaziridine |
C0056820 | null | null | cyclosporin diaziridine |
C0008666 | A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification. | Chromosome pair 3|chromosome 3|Chromosome pair 3 (cell structure)|3 chromosomes|Chromosome 3|3 chromosome | Chromosomes, Human, Pair 3 |
C0282185 | null | antishock trousers|pneumatic antishock garment|Trousers, Anti-Shock|Antishock wear system trousers (physical object)|Antishock wear system trousers|mast trousers|Anti-Shock Trousers|TROUSERS, ANTI-SHOCK|mast trouser|Anti Shock Trousers|Trousers, Antishock|medical anti-shock pants|Antishock Trousers|anti shock trousers | Anti-Shock Trousers |
C0282185 | null | antishock trousers|pneumatic antishock garment|Trousers, Anti-Shock|Antishock wear system trousers (physical object)|Antishock wear system trousers|mast trousers|Anti-Shock Trousers|TROUSERS, ANTI-SHOCK|mast trouser|Anti Shock Trousers|Trousers, Antishock|medical anti-shock pants|Antishock Trousers|anti shock trousers | Anti-Shock Trousers |
C0282185 | null | antishock trousers|pneumatic antishock garment|Trousers, Anti-Shock|Antishock wear system trousers (physical object)|Antishock wear system trousers|mast trousers|Anti-Shock Trousers|TROUSERS, ANTI-SHOCK|mast trouser|Anti Shock Trousers|Trousers, Antishock|medical anti-shock pants|Antishock Trousers|anti shock trousers | Anti-Shock Trousers |
C0023038 | Incision into the side of the abdomen between the ribs and pelvis. | Laparotomies|Laparotomy, NOS|laparotomy procedure|Opening of peritoneal cavity|explorative laparotomy|laparotomies|Coeliotomy|Laparotomy|Celiotomy|laparotomy|celiotomy|Opening of abdomen|Opening of peritoneum|Laparotomy (procedure)|Celiotomy, NOS | Laparotomy |
C0023607 | A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. | Interstitial Cell Stimulating Hormone|Lutropin|Hormone, Interstitial Cell-Stimulating|luteinizing hormone (LH)|Gonadotropin, luteinizing hormone|Luteinizing Hormone|Pituitary interstitial cell stimulating hormone|Hormone, Luteinizing|ICSH|Luteotropin|luteinizing hormone|Interstitial Cell-Stimulating Hormone|ICSH (interstitial cell stimulating hormone)|icsh|ICSH (Interstitial Cell Stimulating Hormone)|LUTEINIZING HORMONE|Luteinising hormone|INTERSTITIAL CELL-STIMULATING HORMONE|Luteinizing gonadotropic hormone|luteinising hormone|interstitial cell stimulating hormone|LH|interstitial cell-stimulating hormone|LH (Luteinizing Hormone)|Pituitary luteinising hormone|Pituitary luteinizing hormone (substance)|Luteinizing hormone|Interstitial cell stimulating hormone (ICSH), pituitary|Luteotropic hormone|lutropin|leuteinizing hormone|Pituitary luteinizing hormone | luteinizing hormone |
C0733758 | A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. | follicle stimulating hormone|Follicular stimulating hormone|Follicle Stimulating Hormone|Follicle stimulating hormone (FSH), pituitary|FOLLICLE STIMULATING HORMONE|follicle stimulating fsh hormone|FOLLITROPIN|follicular stimulating hormone|Product containing pituitary follicle stimulating hormone (medicinal product)|follitropin|Follicle stimulating hormone preparation|follicle-stimulating hormone|Follicle-stimulating hormone|Pituitary follicle stimulating hormone-containing product|follicle hormone stimulating|follicular hormones stimulating|follicle hormones stimulating|Follitropin|Pituitary follicle stimulating hormone (substance)|FSH|fshs|Follicle-Stimulating Hormone|FSH (Follicle Stimulating Hormone)|Pituitary follicle stimulating hormone|FSH preparation|Follicle stimulating hormone | follicle stimulating hormone |
C0733758 | A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. | follicle stimulating hormone|Follicular stimulating hormone|Follicle Stimulating Hormone|Follicle stimulating hormone (FSH), pituitary|FOLLICLE STIMULATING HORMONE|follicle stimulating fsh hormone|FOLLITROPIN|follicular stimulating hormone|Product containing pituitary follicle stimulating hormone (medicinal product)|follitropin|Follicle stimulating hormone preparation|follicle-stimulating hormone|Follicle-stimulating hormone|Pituitary follicle stimulating hormone-containing product|follicle hormone stimulating|follicular hormones stimulating|follicle hormones stimulating|Follitropin|Pituitary follicle stimulating hormone (substance)|FSH|fshs|Follicle-Stimulating Hormone|FSH (Follicle Stimulating Hormone)|Pituitary follicle stimulating hormone|FSH preparation|Follicle stimulating hormone | follicle stimulating hormone |
C0146495 | Protein PML (882 aa, ~98 kDa) is encoded by the human PML gene. This protein plays a role in both transcriptional regulation and PML body formation. | Transcription Factor PML|PML|RING Finger Protein 71|Promyelocytic Leukemia Protein|Protein PML|Tripartite Motif-Containing Protein 19|Tripartite Motif Protein TRIM19|TRIM19|Inducer of Promyelocytic Leukemia Protein | Probable Transcription Factor PML |
C0251385 | null | AsF 69-28 peptide | asialofetuin 69-28 peptide |
C0251385 | null | AsF 69-28 peptide | asialofetuin 69-28 peptide |
C0002059 | An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1. | Alkaline phosphatase|alkaline phosphomonoesterase|Alk Phos|Alkaline Phosphatase|ALKP|Orthophosphoric-monoester phosphohydrolase (alkaline optimum)|Glycerophosphatase|glycerophosphatase|Phosphatase, Alkaline|AlkPhos|ALP - Alkaline phosphatase|ALKALINE PHOSPHATASE|Alkaline phosphomonoesterase|Phosphomonoesterase|AP|phosphomonoesterase|alkaline phosphatase (ALP)|AP - Alkaline phosphatase|Alkaline phosphatase (substance)|alkaline phosphatases|alkaline phosphatase|ALP | Alkaline Phosphatase |
C0001476 | Cation-transporting proteins that utilize the energy of ATP hydrolysis for the transport of CALCIUM. They differ from CALCIUM CHANNELS which allow calcium to pass through a membrane without the use of energy. | Ca2+ transporting ATPase|Calcium pump|calcium adenosine triphosphatase|Calcium-ATPase|Ca(2+)-Transporting ATPase|calcium pump|Calcium Adenosinetriphosphatase|Calcium ATPase|Ca2+ ATPase|ATPase, Ca2+|ATPases, Calcium-Transporting|calcium ATPase|ATPase, Calcium|Calcium-Transporting ATPases|Ca<sup>2+</sup>-transporting adenosine triphosphatase (substance)|Ca<sup>2+</sup>-transporting adenosine triphosphatase|Ca^2+^-transporting ATPase|calcium transporting ATPase|Calcium Adenosine Triphosphatase|Ca2+-transporting adenosine triphosphatase|Ca2+-transporting ATPase|Calcium Transporting ATPases|Ca2+-transporting adenosine triphosphatase (substance)|Ca^2+^-transporting adenosine triphosphatase (substance)|Ca^2+^-transporting adenosine triphosphatase|Triphosphatase, Calcium Adenosine|Adenosine Triphosphatase, Calcium|Adenosinetriphosphatase, Calcium|ATP phosphohydrolase (Ca(2+)-transporting)|Ca<sup>2+</sup>-transporting ATPase | Ca(2+)-Transporting ATPase |
C0044549 | A synthetic analog of lysophosphatidylcholine, an ether lipid, possessing anti-leishmanial and antineoplastic activity. The mechanism of action for edelfosine has not been fully elucidated. Targeting cellular membranes, edelfosine modulates membrane permeability, membrane lipid composition, and phospholipid metabolism. Edelfosine also inhibits the phosphatidylinositol 3 kinase (PI3K)-AKT/PKB survival pathway, possibly activating the pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. In addition, this agent inhibits protein kinase C, intracellular activation of the Fas/CD95 receptor, and intracellular acidification. Anti-leishmanial activity may be due to inhibition of a glycosomal alkyl-specific-acylCoA acyltransferase. (NCI) | 1-O-octadecyl-2-methyl-3-phosphatidylcholine|edelfosine|1-Octadecyl-2-methoxy-rac-glycero-3-phosphocholine|edelfosin|Et-18-OCH3|2-methoxy-PAF|1-octadecyl-2-methyl-sn-glycero-3-phosphocholine|Edelfosine|1-octadecyl-2-methoxyglycero-3-phosphorylcholine|1-octadecyl-2-methoxy-sn-glycero-3-phosphorylcholine|EDELFOSINE|1-octadecyl-2-methylglycero-3-phosphocholine|1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine|ET18-OMe|ET-18-OCH(3)|ET-18-OCH3|1-O-octadecyl-2-O-methylglycerophosphocholine|edelfosinum|1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine|Edelfosinum|ET18-OCH3|1-O-octadecyl-2-O-methyl-glycero-phosphocholine|ET-18-O-methyl | edelfosine |
C0010734 | Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. | Cytidine 5'-(tetrahydrogen triphosphate)|Cytidine triphosphate (CTP)|5'-CTP|Cytidine 5'-(Tetrahydrogen Triphosphate)|Cytidine triphosphate|Deoxycytidine Triphosphate|Cytidine 5'-Triphosphoric Acid|Cytidine 3'-Triphosphate|Cytidine Triphosphate|Cytidine triphosphate (substance)|cytidine triphosphate|cytidine triphosphate (CTP)|CTP|CTP (cytidine triphosphate)|Cytidine-5'-Triphosphate|CRPPP|Triphosphate, Cytidine | Cytidine Triphosphate |
C0024367 | Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal. | Acids, Lysophosphatidic|Lysophosphatidic Acids|lysophospholipid|Lysophospholipids | Lysophospholipids |
C0058836 | A family of high molecular weight GTP phosphohydrolases that play a direct role in vesicle transport. They associate with microtubule bundles (MICROTUBULES) and are believed to produce mechanical force via a process linked to GTP hydrolysis. This enzyme was formerly listed as EC 3.6.1.50. | Dynamins|dynamin|Dephosphin|Dynamin|dephosphin | Dynamin GTPase |
C1179121 | Filaments formed of actin and associated proteins; attached to Z discs at either end of sarcomeres in myofibrils. [ISBN:0815316194] | Thin filament|Actin myofilament|striated muscle thin filament|Thin Filament|Striated muscle thin filament|Myofilamentum tenue | Actin myofilament |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.